Latest Survey Suggests That Currently 20% of Patients With Severe Inflammatory Bowel Disease Currently Receive an Early Aggressive Treatment Approach
Posted on: Tuesday, 5 February 2008, 09:00 CST
Research and Markets (http://www.researchandmarkets.com/reports/c81823) has announced the addition of "Stakeholder Insight: Inflammatory Bowel Disease - Debate" over early aggressive treatment continues to their offering.
Inflammatory bowel disease (IBD) is a chronic inflammatory condition that affects the gastrointestinal tract causing a number of distressing symptoms such as bleeding, diarrhoea and abdominal pain. IBD includes key subsets Crohns disease and ulcerative colitis, both of which can significantly impact on the quality of life of an individual.
Scope
Analysis of the inflammatory bowel disease market based on a survey of 180 gastroenterologists supported by key opinion leader interviews
Overview of epidemiology and patient segmentation in IBD
Influences on gastroenterologists prescribing behavior and their perception of current brands such as Remicade, Humira, Pentasa, Asacol and Lialda
Assessment of outcomes of treatment with Remicade focusing on treatment failure and reasons for failure
Highlights of this title
Clinical guidelines recommend a step-up treatment approach. However, Datamonitors survey suggests that currently 20% of patients with severe IBD currently receive an early aggressive treatment approach. There is an ongoing debate among Gastroenterologists and Datamonitor believe this approach will become more commonplace in the future.
Remicade remains the first choice biologic therapy in 80% of biologic-naïve patients. However, Humira has distinct advantages over Remicade that will lead to strong. Humira is positioned as a treatment for Remicade-failure patients, but Datamonitors survey suggests currently only 30% of these patients go on to receive Humira.
Shires Lialda (mesalazine), recently launched as a once-daily drug, is perceived by gastroenterologists to perform well on patient compliance. In a drug class where there is little differentiation between brands over efficacy and safety, Lialda will provide a clinical advantage thanks to its improved dosing regimen.
Key reasons to purchase this title
Target prescribers more effectively, through an understanding of prescribing behavior and influencing factors
Validate new product forecasting based on diagnosis and treatment rates, and the likely rate of uptake for new products
Benchmark brand awareness and perceptions surrounding product positioning in order to formulate competitive lifecycle management strategies
Content Outline:
ABOUT US HEALTHCARE
CHAPTER 1 EXECUTIVE SUMMARY
CHAPTER 2 INTRODUCTION AND SCOPE
CHAPTER 3 COUNTRY TREATMENT TREES
CHAPTER 4 EPIDEMIOLOGY AND PATIENT SEGMENTATION
CHAPTER 5 DIAGNOSIS OF INFLAMMATORY BOWEL DISEASE
CHAPTER 6 TREATMENT OPTIONS AND GUIDELINES
CHAPTER 7 TREATMENT TRENDS
CHAPTER 8 PRESCRIBING INFLUENCES
CHAPTER 9 BRAND ASSESSMENT
BIBLIOGRAPHY
APPENDIX A
APPENDIX B
APPENDIX C
List of Tables
List of Figures
Companies Mentioned:
Abbott Laboratories
Astralis Ltd.
Bank of Granite Corporation
CMB SA
Elan Corporation, plc
Ferring Pharmaceuticals A/S
IG Group
IMS Health
Insight Communications Company, Inc.
Leucadia National Corporation
Miller Group Limited, The
NICE Systems Ltd
PML Microbiologicals Inc.
Procter & Gamble Company, The
Recordati S.p.A.
Safety Insurance Group, Inc.
Salix Pharmaceuticals,Ltd.
Sanderson Farms Inc
Schiff Nutrition International, Inc
Select Comfort Corp.
Shire plc
Unit Corporation
For more information visit http://www.researchandmarkets.com/reports/c81823
Source: Datamonitor
Source: Business Wire
Related Articles
- Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
- Orexo Initiates Phase II Inflammatory Airway Diseases Trial
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Meyer Pharmaceuticals Acquires NF-kappaB Decoy Technology for Treatment of Inflammatory Disease
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- Micromet and Nycomed Enter Into Exclusive Worldwide Collaboration to Develop and Commercialize Anti-GM-CSF Antibodies for the Treatment of Inflammatory and Autoimmune Diseases
- Cerimon Pharmaceuticals Licenses Exclusive Worldwide Rights to Simulect(R) for the Treatment of Inflammatory Bowel Disease
- Tanox to Acquire Antibodies From Sunol Molecular Corp. For Potential Treatment of Inflammatory Disease, Cancer
- Icagen Initiates Enrollment in Pivotal Phase III Trial of ICA-17043 for the Treatment of Sickle Cell Disease
- Treatment of De Quervain Disease With Triamcinolone Injection With or Without Nimesulide: a Randomized, Double-Blind, Placebo- Controlled Trial
 |
 |
User Comments (0)
RSS Feeds